Buntanetap for Parkinson Disease
Phase-Based Progress Estimates
Effectiveness
Safety
Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease and Related Disorders, Charleston, SC
Parkinson Disease+1 More
Buntanetap - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to measure safety and efficacy of buntanetap capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months. The double-blind treatment duration will be up to 6 months. There will be 5 in-clinic visits and 7 phone calls
Eligible Conditions
- Parkinson Disease
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Other trials for Parkinson Disease
Study Objectives
4 Primary · 5 Secondary · Reporting Duration: Baseline, 1 month, 2 months, 3 months, and 6 months visits
Month 6
Change on Clinical Global Impression of Severity (CGIS) (OFF-state)
Month 6
MDS-Unified Parkinson's Disease Rating Scale Total Score
MDS-Unified Parkinson's Disease Rating Scale Total Score (OFF-state)
Percentage of Responders with "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (ON-state)
Percentage of Responders with "minimally improved," "much improved" or "very much improved" on participant global impression of change
Month 6
MDS-Unified Parkinson's Disease Rating Scale Part II+III
MDS-Unified Parkinson's Disease Rating Scale Part II+III (OFF-state)
Month 8
Safety and tolerability as accessed physical examinations, vital signs, clinical laboratory values, 12-lead ECG, use of concomitant medications, and adverse event (AE) reports
Month 8
Safety and tolerability as accessed by physical examinations, vital signs, clinical laboratory test results, electrocardiogram findings, adverse events (AEs) leading to study discontinuation, drug related AEs, severity of AEs and AEs.
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Other trials for Parkinson Disease
Trial Design
3 Treatment Groups
10 mg Buntanetap,
1 of 3
20 mg Buntanetap
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
450 Total Participants · 3 Treatment Groups
Primary Treatment: Buntanetap · Has Placebo Group · Phase 3
10 mg Buntanetap,
Drug
Experimental Group · 1 Intervention: Buntanetap · Intervention Types: Drug20 mg Buntanetap
Drug
Experimental Group · 1 Intervention: Buntanetap · Intervention Types: DrugPlacebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 1 month, 2 months, 3 months, and 6 months visits
Closest Location: Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease and Related Disorders · Charleston, SC
N/AFirst Recorded Clinical Trial
1 TrialsResearching Parkinson Disease
0 CompletedClinical Trials
Who is running the clinical trial?
TFS Trial Form SupportIndustry Sponsor
19 Previous Clinical Trials
1,374 Total Patients Enrolled
3 Trials studying Parkinson Disease
39 Patients Enrolled for Parkinson Disease
Annovis Bio Inc.Lead Sponsor
3 Previous Clinical Trials
99 Total Patients Enrolled
1 Trials studying Parkinson Disease
75 Patients Enrolled for Parkinson Disease
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:The IUS is a hormonal device that releases hormones into the uterus to stimulate the lining of the uterus.
You have no more than 2 hours of ON-state per day.
You are using oral, intravaginal, or transdermal combined hormonal contraception associated with inhibition of ovulation.
You are using oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments